KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC Meeting Abstract
| Authors: | Rimner, A.; Lai, W. V. V.; Califano, R.; Jabbour, S. K.; Faivre-Finn, C.; Cho, B. C.; Kato, T.; Yu, J.; Yu, L.; Zhao, B.; Pietanza, M. C.; Byers, L. A. |
| Abstract Title: | KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120307035 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS8587 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS8587 -- MSK author Lai lists middle name twice on publisher's record -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work